B.1.617 is now the dominant variant in India.
And we know precious little about it so far in terms of transmissiblity or immune evasion.
And we know precious little about it so far in terms of transmissiblity or immune evasion.
https://twitter.com/chrischirp/status/1385602526578421764
And we also know from @Rukmini (see thread) that the govt's data points on "post-vaccination breakthrough infections" was misleading.
(this may interest you @ArisKatzourakis )
(this may interest you @ArisKatzourakis )
https://twitter.com/Rukmini/status/1385475536177156097?s=20
Another important thread with some much-needed (though preliminary) good news on reduced fatalities among vaccinated populations in Mumbai (i.e. 60+)
The usual caveats apply: incomplete/inadequate data.
The usual caveats apply: incomplete/inadequate data.
https://twitter.com/muradbanaji/status/1385639102255620099?s=20
More good news: vaccine escape unlikely with B.1.617 variant.
question: this is for Covishield (Oxford-Astrazeneca). What about Covaxxin, which accounts for >10 per cent (and perhaps growing) of vaccines administered currently in India?
@ArisKatzourakis
question: this is for Covishield (Oxford-Astrazeneca). What about Covaxxin, which accounts for >10 per cent (and perhaps growing) of vaccines administered currently in India?
@ArisKatzourakis
https://twitter.com/3RakeshMishra/status/1385245798544207875?s=20
• • •
Missing some Tweet in this thread? You can try to
force a refresh
